Acknowledgements

The GISAID sharing mechanism and its data sharing platform are the result of a global collaboration of experts in their respective disciplines working together to facilitate rapid access to data of priority pathogens.

EpiCoV Data Curation Team (January - August 2020)

After COVID-19 was identified as a newly emerging viral respiratory disease and the first hCoV-19 genomes were made available on 10th January 2020 to the scientific community on GISAID’s newly established EpiCoV™ platform, prestigious institutions around the globe came together by contributing experts to GISAID'S team of curators to ensure vast amounts of data could be reviewed and curated in real-time and annotated, prior to release. Their remarkable contribution was key to the unprecedented speed enabling real-time progress in the understanding of the new COVID-19 disease and in the research and development of candidate medical countermeasures.

Stephanie Goya
Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires

Shilpa Yadahalli
Bioinformatics Institute Singapore A*Star

Amandine Perrin
CNRS & Institut Pasteur, Paris

Suma Tiruvayipati
Genome Institute of Singapore A*Star

Paola Cristina Resende Silva
Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro

Amaury Vaysse
CNRS & Institut Pasteur, Paris

Shirleen Soh
Genome Institute of Singapore A*STAR

Christophe Malabat
CNRS & Institut Pasteur, Paris

Erin Chung
Bioinformatics Institute Singapore A*Star

Sarasvathi Easwvaran
Adelaide, Australia

Gabriel Lihue Rojo
Hospital de Niños Dr. Ricardo Gutierrez, Buenos Aires

Deborah Schneider-Luftman
The Francis Crick Institute, London

Emmanuelle Permal
Pasteur Institute, Paris

Yi Hong Chew
Bioinformatics Institute Singapore A*Star

Aengus Stewart
The Francis Crick Institute, London

Sheila Ons
Universidad Nacional de La Plata, Buenos Aires

Thomas Bigot
CNRS & Institut Pasteur, Paris

Daniel See Rui En
Bioinformatics Institute Singapore A*Star

Kirsten Roomp
Luxembourg Centre for Systems Biomedicine

Pablo Soro Barrio
The Francis Crick Institute, London

Natalia Pietrosemoli
CNRS & Institut Pasteur, Paris

Marcos Sterkel
Universidad Nacional de La Plata, Buenos Aires

Richard Mitter
The Francis Crick Institute, London

Mariana Viegas
National Council of Scientific & Technical Research, Buenos Aires

Claudia Chica
CNRS & Institut Pasteur, Paris

Kathryn A. Jackson-Jones
University of Edinburgh, MRC Human Genetics Unit

Raphael Lee Tze Chuen
Bioinformatics Institute Singapore A*Star

Jose Manuel Latorre
National Council of Scientific & Technical Research, Buenos Aires

Hervé Ménager
CNRS & Institut Pasteur, Paris

Gael Millot
CNRS & Institut Pasteur, Paris

Gavin Kelly
The Francis Crick Institute, London

Olov Svartström
Public Health Agency of Sweden

Fernanda Sirota
Bioinformatics Institute Singapore A*Star

Emna Achouri
CNRS & Institut Pasteur, Paris

Lucila Traverso
National Council of Scientific & Technical Research, Buenos Aires

Damien Mornico
CNRS & Institut Pasteur, Paris

Xingyu Zhu
Bioinformatics Institute Singapore A*Star

Corinne Maufrais
CNRS & Institut Pasteur, Paris

Probir Chakravarty
The Francis Crick Institute, London

Xiaofeng Wei
China National GeneBank, Shenzhen

Amine Ghozlane
CNRS & Institut Pasteur, Paris

Quentin Giai Gianetto
CNRS & Institut Pasteur, Paris

Yu Xing Teo
Bioinformatics Institute Singapore A*Star

Lina Wang
China National GeneBank, Shenzhen

Database Access Agreement | Defining GISAID’s data sharing policy

The agreement governing the terms of access to and use of the GISAID platform was developed over 18-months (December 2006 through May 2008) in consultation with national public health, animal health and relevant governmental authorities, the influenza research community, and commercial developers of medical interventions. The process of defining the core terms and conditions was led by Peter Bogner (Principle Investigator), with counsel provided by leading experts in their professional fields, in particular with outstanding contributions by:

Intellectual Property & Technology

- Peter Bogner (Broadcasting Executive, Time Warner International, USA)
- Laurie C. Self (Covington & Burling LLP, Washington D.C.)
- Dale D. Berkley (Intellectual Property Counsel at the National Institutes of Health, Bethesda)
- Joseph A. Foster (Office of the General Counsel, US Centers for Disease Control & Prevention, Atlanta)
- Jörg Paura (Hogan Lovells LLP, Hamburg)

Regulatory & Public Policy

- Mark Abdoo (Global Health Affairs at US Department of Health and Human Services)
- Marie Connett (Cambia - Patent Lens, Canberra Australia)
- Pathom Sawanpanyalert (Ministry of Health, Thailand)
- Endang Sedyaningsih (Ministry of Health, Indonesia)
- Lindsey L. Tonsager (Covington & Burling LLP, Washington D.C.)
- Christoph F. Wetzler (Orrick Hölters Elsing, Frankfurt)

Scientific Policy

- Nancy J. Cox (US Centers for Disease Control & Prevention, Atlanta)
- Rod Daniels (National Institute for Medical Research, London)
- Alan J. Hay (National Institute for Medical Research, London)
- Michael W. Shaw (US Centers for Disease Control & Prevention, Atlanta)

Development of EpiFlu™ v1.0 Database Application

Enabled by a grant from the Max-Planck-Foundation, the Max-Planck Institute for Informatics in Saarbrücken, through its Department of Computational Biology and Applied Algorithmics, under the leadership of Prof. Dr. Thomas Lengauer, was GISAID's first technology partner, contributing substantially to the build up of the first EpiFlu database application. Concept and scientific guidance for the development was provided by experts from National Influenza Centers, WHO CC's and FAO-OIE reference labs.

Concept and scientific guidance for the development of v1.0 by:

- Catherine Smith (WHO’CC at US Centers for Disease Control & Prevention, Atlanta)
- Naomi Komadina (WHO’CC for Reference and Research on Influenza, Melbourne)
- Rebecca Garten (WHO’CC at US Centers for Disease Control & Prevention, Atlanta)
- Vicki Gregory (WHO’CC at National Institute for Medical Research, London)
- Mia Brytting (Swedish National Influenza Center, Stockholm)
- Alice Fusaro (FAO-OIE Ref Lab at Istituto Zooprofilattico Sperimentale delle Venezie, Padua)
- Isabella Monne (Istituto Zooprofilattico Sperimentale delle Venezie, Padua)
- Brunhilde Schweiger (Robert-Koch-Institute, Berlin)

The EpiFlu v1.0 development team was led by Dr. Joachim Büch, Principle Investigator. Georg Friedrich (back-end development), Gunter Bach and Ali Djaoui (front-end development), Kirsten Roomp (data curation), Ruth Christmann (administrative support)

Additional Acknowledgements

- Martin Beer (FAO-OIE Ref Lab at Friedrich-Loeffler-Institute, Greifswald)
- Seiichiro Fujisaki (WHO’CC at National Institute of Infectious Diseases, Tokyo)
- Dirk Höper (FAO-OIE Ref Lab at Friedrich-Loeffler-Institute, Greifswald)
- David Handojo Muljono (Eijkman Institute, Jakarta)
- Vivi Setiawati (National Institute of Health Research and Development, Jakarta)
- Elke Starick (FAO-OIE Ref Lab at Friedrich-Loeffler-Institute, Greifswald)
- Thorsten Wolff (Robert-Koch-Institute, Berlin)
- Lan Yu (WHO’CC at China National Influenza Center, Beijing)

- Joachim Büch et al, poster presented at Options for the Control of Influenza VII, Hong Kong 2010
- Joachim Büch et al, poster presented at Options for the Control of Influenza X, Singapore 2019